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Computer Modeling of Drug-Protein Interactions Between Derivatives of Aricept® and 
Human Acetylcholinesterase
Josh Zhang, ’07, and Dr. John Lutton
Department of Chemistry, Kenyon College, Summer Science 2005
Question: Using molecular modeling techniques on a personal computer, do analogs of Aricept® exist that are more energetically stable than Aricept®?
Abstract
Aricept, a drug used in reducing symptoms of Alzheimer’s disease (AD), was docked into Human 
Acetylcholinesterase. Chemical structure of Aricept was modified with methyl, hydroxyl, amine, chloro, and 
carbonyl groups to test for relative stability between the drug and the protein. Calculations were performed in 
Hyperchem Professional 7.5 using MM+ force field mode. Out of 29 trials run, 14 trials showed improved 
stability over Aricept, and 6 trials showed improvements of ∆G greater than 2 kcal/mol.
Introduction
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease characterized in the brain by 
abnormal clumps (amyloid plaques) and tangled bundles of fibers (neurofibrillary tangles) composed of 
misplaced proteins (1). It is estimated that nearly five million individuals in the United States alone are 
affected by this brain disorder that gradually destroys a person’s memory and ability to learn, reason, make 
judgments, communicate and carry out daily activities (2). 
Current research for AD cures has focused on inhibiting Human Acetylcholinesterase (AChE), an enzyme 
that catalyzes the hydrolysis of acetylcholine into choline and acetic acid. This enzyme functions at the base 
of a 20Å deep active site gorge. Thus, with AChE inhibited, more acetylcholine will be produced and made 
available to the brain. Acetylcholine is a critical neurotransmitter used in forming and keeping memories. It is 
believed that by increasing acetylcholine levels these drugs slow down the progress of dementia caused by 
AD. Aricept is a reversible inhibitor of AChE, known chemically as (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-
(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride. Aricept is commonly referred to in the 
pharmacological literature as E2020.
Aricept, also known as Donepezil, has an empirical formula of C24H29NO3HCl and a molecular weight of 
415.96, and has the following structure:
Aricept is a white crystalline powder and is freely soluble in chloroform, soluble in water and in glacial acetic 
acid, slightly soluble in ethanol and in acetonitrile and practically insoluble in ethyl acetate and in n-hexane 
(3).
Figure 1. Aricept bound to active site of Human 
Acetylcholinesterase
Methods
The structure of human 
acetylcholinesterase complexed with 
fasciculin was obtained from the NIH 
Protein Database. Since no pdb (protein 
database) files for human AChE 
complexed with Aricept® existed in the 
database, fasciculin was removed from 
the human AChE and Aricept® was 
inserted into its active site. Data obtained 
by previous research (Becca Palacios, 
Summer 2002) was analyzed, and 29 
promising structures of the 230 
modifications performed by Palacios was 
examined for conformational stability. 
Aricept® was modified by adding or 
deleting various methyl, amine, hydroxyl, 
chloro, and carbonyl groups. 
Results
Aricept® was successfully and stably docked into the active site of human AChE. The protein-drug binding energy determined by Hyperchem was 
-5418.418 kcal/mol. Of the 29 modification trials ran for Aricept®, 14 trials had greater binding stability than Aricept®, and 6 compounds (A-F) 
showed an increased stability of 2 kcal/mol or more. Table 1 shows a summary of these more stable compounds.
Table 1. Structure, relative binding energy, and predicted binding constant Ki of the six most stable analogs of Aricept® 
Discussion and Future Studies
This data shows that analogs of Aricept® show potential for increased binding stability for human acetylcholinesterase, and thus become a 
valuable instrument in finding cures for Alzheimer’s. These more stable modifications, particularly the compounds that exhibited increased stability 
of 2 kcal/mol, may be studied in future experiments.
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